OCEANIC-AF trial reveals inferiority of asundexian to apixaban for stroke prevention

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

Safe Supply and Origin Therapeutics Receive Conditional Approval for Listing On the CSE | Psychedelic Invest

Safe Supply Streaming Co. Ltd. (“Safe Supply” or the “Company”) and Origin Therapeutics Holdings Inc. (“Origin”) (CSE: ORIG) are pleased to announce that they have received

October 10, 2023

Chiesi champions new inhaler propellant to reduce carbon footprint

Share this article Chiesi hopes to lower Scope 3 emissions by changing the propellant used in its inhalers, said Harriet Lewis, director of market access

April 22, 2024

Pα+: A Nue Lease of Life? Beckley Waves Acquires Struggling At-Home Ketamine Provider Nue Life Health – Psychedelic Alpha

Late last month, psychedelic venture studio Beckley Waves announced that it had acquired Nue Life, an at-home ketamine provider. (Nue Life was acquired by NueCo

November 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.